MedDeviceGuideMedDeviceGuide
Back

Indonesia Medical Device Registration: The Complete Guide for Foreign Manufacturers

How to register medical devices in Indonesia — BPOM/MoH classification, CSDT dossier, Regalkes online system, local representative requirements, Halal certification deadlines, and practical market entry guidance.

Ran Chen
Ran Chen
2026-04-0329 min read

Why Indonesia Matters for Medical Device Companies

Indonesia is the largest medical device market in Southeast Asia, with medical device imports exceeding USD 3 billion annually. With a population of over 280 million people spread across more than 17,000 islands, the country presents both an enormous commercial opportunity and a distinctive set of regulatory and logistical challenges for foreign manufacturers.

Healthcare spending in Indonesia has grown significantly over the past decade, driven by expanding universal health coverage under the Jaminan Kesehatan Nasional (JKN) program launched in 2014, a rising burden of non-communicable diseases, an aging population, and government investment in hospital infrastructure. The JKN program now covers more than 200 million people, making it one of the largest single-payer healthcare systems in the world.

Indonesia's medical device market is heavily import-dependent. Domestic manufacturing accounts for a relatively small share of the market, concentrated in lower-technology segments such as consumables, basic surgical instruments, and hospital furniture. Most higher-technology devices — imaging systems, cardiovascular implants, advanced diagnostics, and surgical robotics — are imported. This dependence on imports creates a persistent and growing demand for foreign medical devices across all risk classes.

For manufacturers already operating in the US, EU, or other Asia-Pacific markets, Indonesia represents a logical expansion target. But the regulatory system has its own classification rules, dossier requirements, online submission platform, local representative mandates, and a Halal certification requirement that has no equivalent in Western regulatory frameworks. This guide covers every aspect of medical device registration in Indonesia so you can plan your market entry with confidence.

Regulatory Authority Overview

Ministry of Health (Kemenkes)

Medical devices in Indonesia are regulated by the Ministry of Health (Kementerian Kesehatan, or Kemenkes) through the National Agency of Drug and Food Control (Badan Pengawas Obat dan Makanan, or BPOM). The Directorate General of Pharmaceuticals and Medical Devices within the Ministry of Health sets policy, while BPOM handles operational aspects of registration, including pre-market review and post-market surveillance.

Key Regulatory Bodies

Body Role
Ministry of Health (Kemenkes) Policy-setting authority for medical devices; oversees the regulatory framework
BPOM Operational regulatory authority; reviews registration applications, issues distribution permits, conducts post-market surveillance
Directorate of Medical Device Production and Distribution Manages the registration process, classification, and technical review
Regalkes (Sistem Informasi Manajemen Alat Kesehatan) The online platform for medical device registration submissions (regalkes.kemkes.go.id)

Legal Framework

The regulatory system is built on several key legal instruments:

Instrument Description
Law No. 36 of 2009 on Health The overarching health law establishing government authority over health products including medical devices
Government Regulation No. 72 of 1998 Original regulation on pharmaceutical and medical device security
Minister of Health Regulation (Permenkes) on Medical Devices Detailed regulations governing medical device classification, registration, distribution, and post-market obligations
BPOM regulations and circular letters Operational guidance on registration procedures, dossier requirements, and technical standards

Indonesia has adopted the ASEAN Medical Device Directive (AMDD) framework, which means its regulatory structure will be familiar to manufacturers who have registered devices in other ASEAN member states. The AMDD's Common Submission Dossier Template (CSDT) format is used as the basis for registration submissions, though Indonesia has additional national requirements that go beyond the standard CSDT.

Key point: For a broader understanding of the AMDD framework and how Indonesia compares to other ASEAN markets, see our guide to medical device registration in Southeast Asia.

Device Classification System

Indonesia follows the AMDD risk-based classification system with four classes. Classification is determined based on the intended purpose of the device, the duration of patient contact, the degree of invasiveness, and whether the device is active (requires a power source). The classification rules are aligned with the GHTF/IMDRF framework.

Classification Overview

Class Risk Level Examples Registration Pathway
Class A Low risk Tongue depressors, bandages, reusable surgical instruments, wheelchairs, hospital beds Notification license (simplified process)
Class B Low-moderate risk Hypodermic needles, suction equipment, powered wheelchairs, ultrasound diagnostic devices, contact lenses New registration (full review)
Class C Moderate-high risk Ventilators, bone fixation plates, hemodialysis equipment, infusion pumps, endoscopes New registration (full review)
Class D High risk Cardiac stents, pacemakers, breast implants, heart valves, HIV diagnostic tests New registration (in-depth review)

Classification Rules

The AMDD classification system uses 16 rules organized into categories:

Rule Category Rules Covers
Non-invasive devices Rules 1-4 Devices contacting intact skin only, channeling or storing bodily liquids
Invasive devices Rules 5-8 Body cavity devices, surgically invasive devices (transient, short-term, long-term), implantable devices
Active devices Rules 9-12 Active therapeutic devices, active diagnostic devices, devices administering energy or substances
Special rules Rules 13-16 Devices incorporating medicinal substances, devices for contraception, disinfection/sterilization devices, devices using animal tissues

IVD Classification

In vitro diagnostic devices follow the same four-class system but with classification rules specific to IVDs. IVD classification considers the intended purpose of the test, the risk to public health if the test fails, and the personal health impact of an incorrect result:

IVD Class Examples
Class A Specimen collection containers, culture media (general purpose), clinical chemistry instruments
Class B Pregnancy tests, urine test strips, clinical chemistry reagents, blood glucose monitors
Class C Rubella IgG tests, blood glucose monitoring systems for diagnosis of diabetes, PSA tests
Class D HIV tests, hepatitis B/C tests, blood group typing reagents, NAT blood screening assays

Practical note: Do not assume your Indonesia classification will match your FDA, EU, or other ASEAN country classification. While the AMDD framework is harmonized, each country may interpret classification rules differently. Always verify your classification under Indonesian rules before preparing your submission.

Prerequisites Before Registration

Before a foreign manufacturer can submit a registration application in Indonesia, several prerequisites must be in place. These are non-negotiable and should be addressed early in your market entry planning.

Local Authorized Representative (LAR)

Foreign manufacturers that do not have a legal entity in Indonesia must appoint a Local Authorized Representative (LAR). The LAR acts as the liaison between the manufacturer and BPOM/Kemenkes and is legally responsible for the device in Indonesia. The LAR holds the registration (Distribution Permit / NIE) on behalf of the foreign manufacturer.

Key requirements for the LAR:

  • Must be an Indonesian legal entity
  • Must hold an IDAK (Izin Distribusi Alat Kesehatan) — a medical device distribution license
  • Must have a physical office and storage facility in Indonesia that meets Good Distribution Practice (GDP) requirements
  • Is responsible for pharmacovigilance and adverse event reporting to BPOM
  • Holds the NIE (Nomor Izin Edar) — the distribution permit that constitutes market authorization

PT PMA Option (Foreign-Owned Company)

As an alternative to using a third-party LAR, foreign manufacturers can establish a PT PMA (Perseroan Terbatas Penanaman Modal Asing) — a foreign-owned limited liability company registered in Indonesia. A PT PMA allows the manufacturer to maintain greater control over regulatory affairs, distribution, and commercial operations.

Advantages of the PT PMA route:

  • Direct control over your registration and NIE
  • Ability to hold your own IDAK distribution license
  • Greater control over pricing, distribution, and commercial strategy
  • Reduced dependency on a third-party distributor

Considerations:

  • Requires capital investment in Indonesia (minimum paid-in capital requirements apply)
  • More complex and costly to establish than appointing an LAR
  • Subject to Indonesian corporate law, tax obligations, and employment regulations
  • Foreign ownership limits may apply to certain business categories

IDAK Distribution License

The IDAK (Izin Distribusi Alat Kesehatan) is the medical device distribution license issued by the Ministry of Health. Any entity that distributes medical devices in Indonesia — whether a local distributor, a PT PMA, or an LAR — must hold an IDAK.

IDAK requirements include:

  • Indonesian legal entity registration
  • Physical warehouse and storage facilities meeting Good Distribution Practice (GDP) standards
  • Qualified personnel with relevant training in medical device handling and storage
  • Standard operating procedures for distribution, complaint handling, and recall management

Choosing Between LAR and PT PMA

Factor LAR (Third-Party) PT PMA
Setup time 2-4 weeks to appoint 3-6 months to incorporate
Control over registration LAR holds NIE; you depend on the relationship You hold NIE directly
Capital investment Minimal Significant (paid-in capital required)
Distribution control Limited; LAR controls distribution channels Full control
Regulatory compliance LAR handles local requirements You handle local requirements
Suitability First market entry, testing the market, lower-volume products Established market presence, high-volume products, strategic long-term investment

Critical advice: The choice of LAR is one of the most consequential decisions you will make for Indonesia. The LAR holds your registration, and changing LARs requires a formal variation application. Choose a partner with a proven track record in medical device registration, adequate regulatory affairs capacity, and a distribution network aligned with your commercial strategy.

Registration Pathways

Standard Registration Process

The registration process in Indonesia follows a defined sequence:

  1. Device classification — Determine the risk class under AMDD rules
  2. Appoint LAR or establish PT PMA — Secure your local representation
  3. Prepare CSDT dossier — Compile the documentation package according to ASEAN CSDT requirements, adapted for Indonesian national requirements
  4. Account setup on Regalkes — Register an account on the online submission system
  5. Online submission — Upload the dossier through Regalkes
  6. Administrative review — BPOM checks completeness of the application
  7. Technical review — Detailed review of technical documentation, labeling, clinical evidence, and quality system information
  8. Correction rounds — If deficiencies are identified, the applicant is given the opportunity to respond and provide additional information
  9. Approval and NIE issuance — If the review is successful, the NIE (Nomor Izin Edar) is issued
  10. Post-market compliance — Ongoing vigilance, reporting, and renewal obligations

Registration by Device Class

Device Class Application Type Review Level
Class A Notification License (simplified) or New Registration Administrative review; limited technical review
Class B New Registration Full technical review
Class C New Registration Full technical review with detailed assessment of clinical evidence
Class D New Registration In-depth technical review; may require additional documentation and longer review

The Regalkes Online System

Overview

Regalkes (Sistem Informasi Manajemen Alat Kesehatan) is the Ministry of Health's online platform for medical device registration. All registration applications, variations, renewals, and related submissions must be made through Regalkes at regalkes.kemkes.go.id.

Account Setup

To use Regalkes, the LAR or PT PMA must:

  1. Register a corporate account on the Regalkes platform
  2. Provide company registration documents (NPWP tax number, NIB business registration, IDAK)
  3. Designate authorized users with appropriate access levels
  4. Complete the account verification process

Submission Workflow

The Regalkes system supports the following workflows:

Function Description
New registration Submit a new device for market authorization
Notification Simplified process for Class A devices
Variation (change) Submit changes to an existing registration (manufacturer details, device specifications, labeling, etc.)
Renewal Renew an existing NIE before expiration
Renewal with variation Combine renewal with changes to the registration
Correction response Respond to deficiency letters from BPOM reviewers

Document Upload Requirements

Documents submitted through Regalkes must be in PDF format, properly signed and stamped where required, and organized according to the CSDT structure. File size limits apply, and large documents may need to be split into sections. All documents must be in English or Bahasa Indonesia. Some documents may require notarization or legalization.

Practical tip: Ensure your LAR has experience with the Regalkes system. Errors in document formatting, incorrect file naming, or incomplete uploads are common causes of administrative rejection, which resets the review clock.

CSDT Documentation Requirements

Indonesia requires the ASEAN Common Submission Dossier Template (CSDT) as the basis for registration submissions. The CSDT is structured into specific sections, each addressing a different aspect of the device's safety, performance, and quality.

CSDT Structure

CSDT Section Content Required for Classes
Section 1: Administrative Information Application forms, local representative details, regulatory status in other countries, product owner authorization letter A, B, C, D
Section 2: Table of Contents Complete dossier table of contents A, B, C, D
Section 3: Executive Summary Device description, intended purpose, regulatory history, indications for use A, B, C, D
Section 4: Essential Principles Checklist demonstrating compliance with Essential Principles of Safety and Performance, with references to supporting evidence A, B, C, D
Section 5: Device Description Detailed description of the device, materials, design features, principles of operation, variants, accessories A, B, C, D
Section 6: Labeling Labels, instructions for use (IFU), packaging information A, B, C, D
Section 7: Risk Analysis Risk management documentation per ISO 14971, including risk assessment, risk mitigation, and residual risk evaluation A, B, C, D
Section 8: Design Verification and Validation Bench testing, biocompatibility, electrical safety, electromagnetic compatibility, software verification and validation, usability data B, C, D (limited for A)
Section 9: Clinical Evidence Clinical evaluation report, clinical investigation data, literature review B, C, D (limited for A)
Section 10: Manufacturing Information Quality management system evidence, ISO 13485 certificate, manufacturing process description, sterilization validation A, B, C, D
Section 11: Other Documentation Stability data, shelf life studies, compatibility data, other supporting information As applicable

Forms A Through E

The CSDT includes standardized forms for different purposes:

Form Purpose
Form A Application for pre-market evaluation of a medical device
Form B Summary of regulatory status in other countries (where the device is already marketed)
Form C Declaration of conformity with Essential Principles of Safety and Performance
Form D Summary of design verification and validation data
Form E Summary of clinical evidence

ISO 13485 Requirement

ISO 13485 certification is expected as proof of quality management system compliance. BPOM will review the manufacturer's ISO 13485 certificate as part of the dossier. The certificate should be current, issued by an accredited certification body, and cover the scope of the devices being registered.

Important: If you are working on ISO 13485 certification, our ISO 13485 certification guide provides a comprehensive overview of the standard and certification process.

Documentation Tips

  • Regulatory history in other countries is valuable. Include information about FDA clearance, CE marking, TGA approval, and registrations in other ASEAN countries. This can support the technical review and reduce the number of deficiency questions.
  • Labeling must comply with Indonesian requirements. Labels and instructions for use should include information in Bahasa Indonesia, or at minimum, Bahasa Indonesia translations of critical safety information.
  • Clinical evidence can be leveraged from existing data. Literature-based clinical evaluations and clinical data from other jurisdictions are generally accepted, though BPOM may request additional data for certain device types.
  • Photographs and diagrams help. Include clear photographs of the device, packaging, and labeling in the dossier.

Special Requirements

HIV Diagnostic Products

HIV diagnostic devices face additional scrutiny in Indonesia. These products, classified as Class D, may require additional documentation demonstrating clinical performance in the Indonesian population, sensitivity and specificity data, and compliance with national HIV testing guidelines. The review process for HIV diagnostics is typically more rigorous and may take longer than standard Class D devices.

Radiation-Emitting Devices

Medical devices that emit ionizing radiation (X-ray equipment, CT scanners, fluoroscopy systems) require additional clearances. These devices must comply with radiation safety standards set by the National Nuclear Energy Agency (BATAN) or the relevant radiation protection authority. Radiation safety documentation and shielding calculations may need to be submitted alongside the standard CSDT dossier.

Animal-Origin Materials

Devices containing or derived from animal tissues, cells, or materials (e.g., bovine collagen, porcine heart valves, gelatin-based hemostats) face additional requirements:

  • Documentation of animal sourcing and origin
  • Evidence of viral inactivation or removal during manufacturing
  • Risk assessment for transmissible spongiform encephalopathies (TSE)
  • Compliance with international guidelines for animal-derived materials

Halal certification implications: Devices containing animal-derived materials that have not been certified Halal must already carry a "Non-Halal" label if Halal certification is not obtained. Given Indonesia's mandatory Halal certification requirements (discussed below), this is a significant consideration for manufacturers of such devices.

Software and Digital Health

Software as a Medical Device (SaMD) and devices incorporating software must provide software lifecycle documentation consistent with IEC 62304. This includes:

  • Software development process description
  • Software risk management (per IEC 62304 and ISO 14971)
  • Software verification and validation evidence
  • Software version history and change log
  • Cybersecurity documentation where applicable

Review Timelines and Process

Revised 2025/2026 Timelines

In 2025, Indonesia revised its review timelines. The updated timelines (in working days) are as follows:

Application Type Device Class Previous Timeline (Working Days) Revised Timeline (Working Days)
Notification License A 7 12
New Registration A 15 21
New Registration B 30 36
New Registration C 30 36
New Registration D 45 55
Renewal A-D 7 13
Variation (Change) A-D 10 16
Renewal with Variation A-D 10 16

Correction Rounds

The revised timeline framework also updated the correction round (deficiency response) process:

Application Type Device Class Previous Correction Rounds Revised Correction Rounds
Correction Rounds A-C 1 round of 10 working days 2 rounds of 10 working days
Correction Rounds D 1 round of 15 working days 2 rounds of 15 working days

This change is significant. The previous framework allowed only one round of corrections, meaning a single deficiency letter and one opportunity to respond. The revised framework gives applicants two rounds of corrections, providing more opportunity to address reviewer concerns without the application being rejected.

Key takeaway: While the published review timelines have increased compared to the previous framework, the addition of a second correction round may actually reduce the overall risk of rejection. Under the previous single-correction-round system, an incomplete or inadequate response to a deficiency letter could result in outright rejection, requiring a new application from scratch.

What to Expect During Review

The review process typically follows these stages:

  1. Administrative completeness check — BPOM verifies that all required documents have been submitted and are in the correct format. Incomplete submissions are returned without technical review.

  2. Technical review — Reviewers assess the device description, essential principles compliance, risk analysis, clinical evidence, labeling, and quality system documentation. For Class B and C devices, the review focuses on safety and performance. For Class D devices, the review is more detailed and may involve consultation with external experts.

  3. Deficiency letter — If the reviewer identifies issues, a deficiency letter is issued detailing the questions or additional information required. The applicant (through the LAR) must respond within the specified timeframe.

  4. Response evaluation — The reviewer evaluates the response. If deficiencies remain, a second deficiency letter may be issued (under the revised framework). If all issues are resolved satisfactorily, the application proceeds to approval.

  5. NIE issuance — The NIE (Nomor Izin Edar) is issued, granting market authorization for the device.

Timeline Reality Check

Published timelines represent the regulatory authority's target for completing the review. In practice, actual timelines may be longer due to:

  • Incomplete submissions requiring administrative resubmission
  • Deficiency letters and response preparation time
  • Backlogs at BPOM during peak periods
  • Additional questions or clarification requests beyond formal correction rounds
  • Public holidays and government office closures

Plan for total elapsed time from submission to NIE issuance of approximately 3-6 months for Class A devices, 4-8 months for Class B and C devices, and 6-12 months for Class D devices. Complex devices, those requiring extensive correction rounds, or those with novel technology may take longer.

Halal Certification Requirements

Overview

Indonesia has enacted mandatory Halal certification requirements for products including medical devices under the Halal Product Assurance Law (Law No. 33 of 2014) and its implementing regulations. This requirement is administered by the Halal Product Assurance Agency (BPJPH) under the Ministry of Religious Affairs.

For medical device manufacturers, the Halal certification requirement represents a unique consideration that has no direct equivalent in Western regulatory frameworks. Indonesia is the world's largest Muslim-majority country, with approximately 87% of the population identifying as Muslim. The Halal certification requirement reflects the government's commitment to ensuring that products available in the market comply with Islamic law.

Certification Deadlines by Device Class

Halal certification requirements are being phased in by device risk class:

Device Class Halal Certification Deadline
Class A October 17, 2026
Class B October 2029
Class C October 2034
Class D TBD (to be announced)

What Halal Certification Means for Medical Devices

Halal certification for medical devices primarily concerns:

  • Materials sourcing — Whether the device contains any animal-derived materials, particularly from non-Halal-slaughtered animals or porcine sources
  • Manufacturing processes — Whether any non-Halal substances are used during manufacturing, cleaning, or sterilization
  • Traceability — Documentation of the supply chain for all materials used in the device

Key Implications for Manufacturers

Devices with no animal-derived materials: Many medical devices — particularly those made entirely from synthetic materials, metals, and ceramics — may qualify for Halal certification relatively straightforwardly. The certification process involves documentation review and may not require changes to the device or its manufacturing process.

Devices containing animal-derived materials: Devices that contain or are manufactured using animal-derived materials (e.g., collagen scaffolds, gelatin-based products, porcine tissue valves, bovine-derived surgical sealants) face a more complex certification pathway. These devices must demonstrate that animal-derived materials come from Halal-slaughtered sources, or they may need to carry a "Non-Halal" label.

Non-Halal labeling requirement: Devices that contain animal-derived materials and have not obtained Halal certification must carry a "Non-Halal" label. This is not optional — it is a regulatory requirement. The "Non-Halal" label must be clearly visible on the device packaging.

Practical Halal Certification Advice

  • Start the Halal certification process early. Do not wait until the deadline approaches. The certification process can take several months and involves documentation review, potential audits, and administrative processing.
  • Assess your materials supply chain now. Determine whether any of your device materials or manufacturing process inputs are animal-derived. This assessment should cover raw materials, processing aids, lubricants, and cleaning agents.
  • Engage with a Halal certification body. The BPJPH accredits Halal certification bodies (Lembaga Pemeriksa Halal, or LPH) that conduct the assessment. Work with an accredited LPH early in the process.
  • Factor Halal certification into your product development. For new products targeting the Indonesian market, consider Halal compliance during the design phase. Selecting Halal-compliant materials from the outset is far easier than reformulating or redesigning a product after the fact.

Post-Market Obligations

Once a medical device receives its NIE and enters the Indonesian market, the manufacturer and the LAR have ongoing post-market obligations.

Vigilance and Adverse Event Reporting

Indonesia requires reporting of adverse events and incidents involving medical devices. The reporting framework includes:

Report Type Content Timeline
Serious adverse event report Death, life-threatening event, or event requiring hospitalization Within 10 calendar days of awareness
Adverse event report Events that do not meet serious criteria but involve device malfunction or deterioration Within 30 calendar days of awareness
Field safety corrective action (FSCA) report Recalls, modifications, device removals, or safety communications Prior to implementation or immediately upon awareness
Periodic safety update report (PSUR) Summary of safety and performance data over the reporting period Submitted periodically as required by BPOM

E-Reporting

BPOM operates an electronic reporting system for adverse events and safety reports. The LAR is responsible for submitting reports through this system. Reports must be submitted in the format prescribed by BPOM and include sufficient detail for the authority to assess the event and determine whether further action is required.

Post-Market Surveillance

Manufacturers are expected to maintain a post-market surveillance system that collects and analyzes data on device performance in real-world use. This includes:

  • Customer complaint handling and investigation
  • Trend analysis of adverse events and complaints
  • Post-market clinical follow-up where required
  • Periodic review of the risk-benefit balance of the device

Distribution Permit Renewal

The NIE is valid for a specific period (typically 5 years) and must be renewed before expiration. The renewal process requires submission through Regalkes and may involve updated documentation demonstrating continued compliance with regulatory requirements. Plan to start the renewal process at least 6 months before the NIE expiration date to avoid any gap in market authorization.

Labeling and Advertising Compliance

All marketing and promotional materials for medical devices in Indonesia must comply with BPOM regulations. Claims must be consistent with the approved indications for use, and advertising must not be misleading. The LAR is responsible for ensuring that promotional materials comply with local requirements.

Costs and Fees

Government Fees

Registration fees in Indonesia are set by the Ministry of Health and vary by device class and application type. The following table provides the approximate government fees:

Application Type Device Class Official Government Fee (IDR) Approximate USD Equivalent
Notification License A IDR 1,500,000 ~USD 95
New Registration A IDR 1,500,000 ~USD 95
New Registration B IDR 3,000,000 ~USD 190
New Registration C IDR 3,000,000 ~USD 190
New Registration D IDR 5,000,000 ~USD 315
Renewal A IDR 500,000 ~USD 32
Renewal B, C, D IDR 1,000,000 ~USD 63
Variation (Change) A IDR 500,000 ~USD 32
Variation (Change) B, C, D IDR 1,000,000 ~USD 63

Government fees are relatively modest compared to many other regulatory jurisdictions. However, the total cost of registration is significantly higher when all expenses are considered.

Estimated Total Costs

The total cost of medical device registration in Indonesia includes government fees, LAR fees, regulatory consulting fees, translation costs, and Halal certification fees:

Cost Component Estimated Range (USD)
Government registration fees 30-600 per application
LAR fees (annual retainer) 5,000-20,000 per year
Regulatory consulting / dossier preparation 10,000-50,000 per device
Professional translation (English to Bahasa Indonesia) 2,000-8,000 per submission
ISO 13485 certification (if not already held) 15,000-40,000 (one-time, then surveillance audits)
Halal certification 3,000-15,000 per product
Legal / company setup (if establishing PT PMA) 10,000-30,000
Estimated total per device (using LAR route) 20,000-85,000
Estimated total per device (PT PMA route, first year) 30,000-115,000

Note: These estimates are indicative and will vary depending on the complexity of the device, the amount of clinical evidence required, the LAR's fee structure, and whether the manufacturer already holds ISO 13485 certification. The PT PMA route has higher first-year costs due to company establishment but may be more economical over the long term for manufacturers with multiple products.

Practical Tips for Success

1. Choose Your LAR Carefully

The LAR holds your registration and is your legal representative in Indonesia. A poor LAR choice can result in registration delays, lost commercial opportunities, and difficulties changing representatives later. Evaluate potential LARs based on their regulatory affairs expertise, track record with BPOM submissions, responsiveness, distribution network, and the clarity of their contractual terms.

2. Build a Master CSDT Dossier

If you are targeting multiple ASEAN markets, build your technical documentation in CSDT format from the start. The CSDT structure is used across ASEAN member states, and a well-organized master dossier can be adapted for each country with relatively minor modifications to the country-specific sections. This approach saves significant time and cost when expanding to additional ASEAN markets.

3. Leverage Existing Regulatory Approvals

If your device is already approved by a stringent regulatory authority (FDA, EU Notified Body, TGA, Health Canada, MHLW/PMDA), include this information prominently in your dossier. BPOM reviewers take into account regulatory approvals from recognized reference authorities, and this can facilitate a smoother review process. Include copies of FDA 510(k) or PMA letters, CE certificates, and other regulatory approvals in the relevant section of the CSDT.

4. Prepare for Bahasa Indonesia Requirements

While technical documentation can generally be submitted in English, labeling and certain product information may need to be provided in Bahasa Indonesia. Invest in professional medical translation by translators experienced with regulatory documentation. Poor translations are a common cause of deficiency letters.

5. Start Halal Certification Early for Class A Devices

With the October 2026 deadline for Class A devices approaching, manufacturers of Class A products should begin the Halal certification process now. Even if your device uses no animal-derived materials, the administrative process takes time. Waiting until the deadline will result in a rush and potential inability to sell your product legally.

6. Budget Realistic Timelines

The revised 2025 review timelines are published targets. Budget for total elapsed time (from dossier preparation to NIE issuance) of 6-12 months for Class B and C devices, and 9-15 months for Class D devices. Complex devices with novel technology may take longer. Build these timelines into your commercial launch plans.

7. Maintain Document Control

Keep all registration documents, correspondence with BPOM, deficiency letters, and response records organized and accessible. Registration is not a one-time event — you will need this documentation for renewals, variations, and potential audits. Establish a document management system for your Indonesian registrations from the outset.

8. Plan for Distribution Alongside Registration

Registration is only half the battle. Indonesia's hospital procurement landscape is complex, with government tenders, private hospital purchasing, and regional distribution networks all playing a role. Engage with distribution strategy early — ideally during the registration process — so that commercial readiness coincides with regulatory approval.

9. Monitor Regulatory Changes

Indonesia's medical device regulatory framework is evolving. Changes to classification rules, registration procedures, fees, Halal certification requirements, and post-market obligations occur periodically. Maintain a relationship with your LAR or regulatory consultant that includes proactive regulatory intelligence — not just reactive submission support.

10. Understand the Broader ASEAN Strategy

Indonesia is one of several significant ASEAN markets. Consider how your Indonesian registration fits into a broader ASEAN strategy. The CSDT dossier you prepare for Indonesia can be adapted for Thailand, Malaysia, the Philippines, Vietnam, and Singapore. Manufacturers who plan for multi-country ASEAN entry from the outset achieve economies of scale in regulatory investment. For a comprehensive overview of the ASEAN regulatory landscape, see our Southeast Asia registration guide.

Related Resources

For further guidance on topics related to Indonesia medical device registration, explore these additional resources on MedDeviceGuide:

Conclusion

Indonesia's medical device market represents one of the most significant opportunities in the Asia-Pacific region. With a population of 280 million, rapidly expanding healthcare coverage, heavy import dependence for advanced medical technology, and a regulatory framework that is progressively aligning with international standards, it is a market that demands attention from any medical device manufacturer with global ambitions.

The regulatory system — built on the AMDD framework and administered through BPOM and the Regalkes online platform — is structured and navigable. The revised 2025/2026 review timelines, including the addition of a second correction round, reflect a regulatory authority that is maturing and becoming more practical in its approach. The CSDT dossier format means that manufacturers already selling in other ASEAN countries can leverage existing documentation with country-specific adaptations.

The Halal certification requirement is the most distinctive aspect of Indonesia's regulatory environment. With deadlines approaching — October 2026 for Class A devices — manufacturers need to assess their materials supply chains and engage with the Halal certification process now, particularly for devices containing animal-derived materials.

Success in Indonesia comes down to preparation: choosing the right local partner, building a high-quality CSDT dossier, budgeting realistic timelines, addressing Halal certification proactively, and integrating your Indonesian strategy into a broader ASEAN market entry plan. The manufacturers who invest in understanding and respecting the Indonesian regulatory system will find a market that rewards their commitment with substantial commercial opportunity.